Holen Sie sich die Stockscreener-App
59.35
1.88%
-1.14
Handel nachbörslich:
59.50
0.15
+0.25%
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Street Watch: Is Ionis Pharmaceuticals Inc. a cyclical or defensive stockJuly 2025 Catalysts & Consistent Profit Trade Alerts - khodrobank.com
Amyotrophic Lateral Sclerosis Pipeline Outlook 2025: Clinical - openPR.com
Ionis Pharmaceuticals Shares Rise After BMO Capital Upgrade - MarketScreener
Key resistance and support levels for Ionis Pharmaceuticals Inc.M&A Rumor & Daily Stock Trend Reports - Newser
What the charts say about Ionis Pharmaceuticals Inc. todayQuarterly Profit Report & Free Weekly Watchlist of Top Performers - Newser
Citigroup maintains Buy rating, raises Ionis Pharmaceuticals PT to $84 from $69. - AInvest
Is Ionis Pharmaceuticals Inc. stock trending bullish2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - khodrobank.com
Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results - MSN
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride - TradingView
Ionis Pharmaceuticals: BMO Capital Upgrades to Outperform, PT Raised to $70 - AInvest
Market reaction to Ionis Pharmaceuticals Inc.’s recent newsWeekly Trade Review & Long-Term Safe Investment Plans - Newser
Ionis Pharmaceuticals Soars: New Drug Approved - StocksToTrade
Buy IONS Stock After Its 35% Pop? - Trefis
Ionis upgraded at BMO Capital Markets after data for lipid-lowering agent - MSN
Ionis stock upgraded at BMO Capital Markets (IONS:NASDAQ) - Seeking Alpha
Analyzing Ionis Pharmaceuticals Inc. with risk reward ratio charts2025 Major Catalysts & Community Verified Swing Trade Signals - Newser
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up - simplywall.st
Using data filters to optimize entry into Ionis Pharmaceuticals Inc.Buy Signal & Accurate Entry/Exit Alerts - Newser
What’s next for Ionis Pharmaceuticals Inc. stock priceTrade Risk Assessment & Precise Entry and Exit Recommendations - Newser
Ionis Pharmaceuticals Inc. stock prediction for this week2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
MSD, Ionis trumpet lipid-lowering drug data - pharmaphorum
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $70 From $40 - MarketScreener
Will Ionis Pharmaceuticals Inc. bounce back from current supportPortfolio Value Report & Expert Approved Momentum Ideas - Newser
Ionis reports topline outcomes from Phase III trials of olezarsen for sHTG - Yahoo Finance
Ionis Pharmaceuticals shares rise 1.74% premarket after positive Phase 3 study results for olezarsen. - AInvest
Has Ionis Pharmaceuticals Inc. formed a bullish divergenceBuy Signal & Fast Entry Momentum Alerts - Newser
Ionis to present at upcoming September 2025 investor conferences - BioSpace
Comparing Ionis Pharmaceuticals Inc. in custom built stock radarsWeekly Profit Summary & AI Optimized Trade Strategies - Newser
Ionis looks to expand use of lipid-lowering drug after trial hits goal - BioPharma Dive
Narrow-Moat Ionis Expands Its Cardiology and Neurology Portfolio; Positive Long-Term Outlook - Morningstar
Visualizing Ionis Pharmaceuticals Inc. stock with heatmaps2025 Top Gainers & Daily Profit Maximizing Tips - Newser
Ionis reports sHTG win while Arrowhead inks Novartis deal - BioWorld MedTech
IONS Stock Soars: Time to Buy or Stay Cautious? - timothysykes.com
How to use a screener to detect Ionis Pharmaceuticals Inc. breakoutsJuly 2025 Sentiment & Accurate Buy Signal Notifications - Newser
More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off. - Barron's
Ionis Looks Set To Own Its First Blockbuster - insights.citeline.com
Ionis to present at upcoming investor conferences - Business Wire
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies - Stocktwits
Ionis Pharmaceuticals: A High-Conviction Buy Amid a Pivotal Data and Launch Timeline in 2025 - AInvest
FDA Greenlights Ionis’ Dawnzera, Shares Soar - StocksToTrade
Ionis shares surge after drug to lower blood fat shows promise in trials - TradingView
Ionis Pharmaceuticals and the Breakthrough Potential of Olezarsen in Severe Hypertriglyceridemia - AInvest
FDA Grants Approval: Ionis Gains Momentum - timothysykes.com
Ionis Pharma Shares Rise After Reporting 'Positive' Olezarsen Data in Severe Hypertriglyceridemia - MarketScreener
Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news - TradingView
Real time breakdown of Ionis Pharmaceuticals Inc. stock performancePortfolio Performance Report & Long-Term Investment Growth Plans - Newser
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - inkl
Why Is Ionis Pharma Stock Skyrocketing Tuesday?Ionis Pharmaceuticals (NASDAQ:IONS) - Benzinga
Ionis Pharmaceuticals stock holds steady as Stifel maintains $43 target - Investing.com
Ionis Pharmaceuticals stock hits 52-week high at 49.3 USD - Investing.com
Ionis Pharmaceuticals: A High-Conviction Biotech Play Amid Triglyceride-Lowering Breakthroughs and Undervalued Pipeline Potential - AInvest
Transcript : Ionis Pharmaceuticals, Inc.Special Call - MarketScreener
Ionis Pharmaceuticals’ Dawnzera Approval Boosts Stock - StocksToTrade
Ionis Pharma Hits Four-Year High On A 'Home Run' In Triglycerides Treatment - inkl
Positive Phase III results for Ionis’ olezarsen in severe hypertriglyceridemia - The Pharma Letter
Ionis shares jump after drug lowers blood fat levels in advanced trials - TradingView
PepsiCo, Ionis Pharma, United Therapeutics - TradingView
Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener
Sector Update: Health Care - MarketScreener
Ionis Pharmaceuticals Incannounces positive results from phase 3 studies of olezarsenSEC filing - MarketScreener
Leerink Partners Adjusts Price Target on Ionis Pharmaceuticals to $62 From $56, Maintains Outperform Rating - MarketScreener
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG) - BioSpace
Ionis Pharmaceuticals (IONS) Soars 17.32% on FDA Approval - AInvest
Ionis stock soars after olezarsen shows 85% reduction in pancreatitis events - Investing.com
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):